In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure
News|Podcasts|November 10, 2025
ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we explore how AI and tokenized data are improving patient-protocol matching, highlight Caplyta’s new FDA approval for major depressive disorder, and review the FDA’s expansion of its National Priority Voucher program.
This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.
- We begin with Part 3 of a recent
video interview on how AI and tokenized data can improve patient-protocol matching. Matt Holms, vice president of sales at Citeline, explained that delays in clinical trials often stem from site variability, investigator shortages, and complex protocols. By combining proprietary and real-world datasets with tokenization and AI, sponsors can streamline feasibility, match patients to trials more accurately, and maintain privacy compliance—helping create a more efficient and equitable recruitment ecosystem. - Next, the FDA
approved Caplyta as an adjunctive therapy for adults with major depressive disorder. The decision is based on two Phase III trials showing significant improvements in MADRS scores compared with placebo, along with a favorable safety profile. Long-term data from an open-label extension showed that 80% of patients responded to treatment, and 65% achieved remission at six months. This marks Caplyta’s fourth FDA-approved indication, broadening its use in neuropsychiatric care. - Finally, the FDA
added six new therapies to its Commissioner’s National Priority Voucher program, bringing the total to 15. The program targets high-impact public health needs, including obesity, cancer, sickle cell disease, and drug-resistant tuberculosis. It accelerates review timelines from 10-12 months to as little as one to two months using a multidisciplinary “tumor board-style” review model. Recent additions include orforglipron and Wegovy for obesity, highlighting the FDA’s commitment to bringing transformative therapies to patients faster.
That’s all for today’s ACT Brief. Join us tomorrow for more insights shaping the future of clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
Trending on Applied Clinical Trials Online
1
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
2
What It Would Take to Make Community Trials Accessible and Scalable
3
How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?
4
Measuring What Matters: Realigning Clinical Endpoints with Patient Reality
5